OptimizeRx Corporation

NASDAQ:OPRX

Medical - Healthcare Information Services

Healthcare
$7.31 -0.98%

-$0.05 today

Market cap
$138.21M
Beta
1.10
P/E (TTM)
13.8
EPS (TTM)
$0.36
52W Low $4.57High $22.25

Volume 0.18M

Average 0.47M

OPRX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

OptimizeRx CorporationNASDAQ: OPRX

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables grows, but more slowly than its trailing trend

Q1 FY2026 accounts receivables of $5.76M rose 4.9% year over year, behind the +104.9% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -41.4% a year.

Context

  • Accounts receivables amounted to 0.4% of revenue in FY2025, down 1.9 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +4.9% toward the trailing-twelve-month pace of +104.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.76M+266.6% QoQ
Last fiscal yearDec 2025
$460K+121.2% YoY
LTMMar 2026
$198K+104.9% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.9%——
1 year+121.2%——
3-year CAGR-41.4%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
460K USD
Year-over-year change
+121.2%

Accounts Receivables vs competitors

How OPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +104.9% is the 4th highest of 10, against a peer median of -67.1%.
  • Accounts receivables amounts to 0.2% of revenue for OPRX, versus a peer median of 1.1%.
OPRX Competitors
Accounts Receivables for OPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RXSTRxSight, Inc.LTM Mar 2026$8.52M USD+190.0%—6.7%
DHDefinitive Healthcare Corp.LTM Mar 2026$4.29M USD-67.1%—1.8%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$3.43M USD-549.9%—4.2%
SLPSimulations Plus, Inc.LTM Feb 2026$1.68M USD+27.5%-47.2%2.1%
DRUGBright Minds Biosciences Inc.LTM Mar 2026CA$889.96K CAD-378.4%+99.6%—
TBRGTruBridge, Inc.LTM Mar 2026$622K USD-80.6%-37.3%0.2%
SPOKSpok Holdings, Inc.LTM Mar 2026$534K USD-324.4%+3.6%0.4%
NRCNational Research CorporationLTM Mar 2026$494K USD+111.1%-58.3%0.4%
OPRXOptimizeRx CorporationLTM Mar 2026$198K USD+104.9%-41.4%0.2%
NAKANakamoto Inc.LTM Mar 2026$11.39K USD+122.9%—0.3%
Peer median (excluding OPRX) —-67.1%-37.3%1.1%

Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income378.08K(11.44M)(17.57M)(20.11M)5.13M
Depreciation & Amortization1.97M2.02M2.4M4.33M4.33M
Deferred Income Tax0001.45M1.21M
Stock-Based Compensation5.49M15.75M13.72M11.47M6.96M
Change in Working Capital(7.19M)3.96M(15.55M)921K816K
Accounts Receivables(6.99M)2.28M(8.71M)(2.17M)460K
Inventory00000
Accounts Payables(603.09K)555.4K195K(72K)(520K)
Other Working Capital408.65K1.12M(7.03M)3.16M876K
Other Non-Cash Items80K363.51K9.76M6.83M264K
Operating Cash Flow726.04K10.65M(7.24M)4.89M18.72M
Capital Expenditures(486K)(244.57K)(871K)(112K)(58K)
Acquisitions (Net)0(2M)(80.41M)00
Purchases of Investments0(55.93M)(162.78M)00
Sales of Investments00218.71M00
Other Investing Activities(385.68K)(163.56K)(774K)(338K)126K
Investing Cash Flow(486K)(58.18M)(25.34M)(450K)68K
Debt Repayment0036.02M(4M)(8M)
Common Stock Issued70.67M000352K
Common Stock Repurchased0(20.02M)(7.52M)(911K)0
Dividends Paid00000
Other Financing Activities3.25M1.07M(278K)0(1.15M)
Financing Cash Flow73.92M(18.95M)28.22M(4.91M)(8.8M)
Effect of Forex Changes00000
Net Change in Cash74.16M(66.47M)(4.36M)(472K)9.99M
Free Cash Flow240.04K10.41M(8.11M)4.78M18.66M

OptimizeRx Corporation

NASDAQ:OPRX

Intrinsic Alpha fair value

Locked

Current Price

$7.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.